Compass Therapeutics (CMPX) Cash & Equivalents (2018 - 2026)

Compass Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $55.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 32.56% year-over-year to $55.2 million; the TTM figure through Mar 2026 stood at $55.2 million (up 32.56% YoY), while the FY2025 annual figure was $31.2 million, down 29.15% from the prior year.
• Cash & Equivalents came in at $55.2 million for Q1 2026 at Compass Therapeutics, up from $31.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $136.4 million in Q1 2022 to a low of $16.5 million in Q3 2022.
• A 5-year average of $37.6 million and a median of $30.4 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 243.62% in 2022 and slumped 80.19% in 2023, its largest moves.
• Compass Therapeutics' Cash & Equivalents stood at $34.9 million in 2022, then plunged by 30.58% to $24.2 million in 2023, then jumped by 81.82% to $44.1 million in 2024, then slipped by 29.15% to $31.2 million in 2025, then soared by 76.76% to $55.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $55.2 million, $31.2 million, and $46.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison